Neurogene Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Neurogene Inc. (NGNE) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$90.35 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-24
- Neurogene Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$90.35M.
- Neurogene Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$75.14M.
- Neurogene Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$36.32M.
- Neurogene Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$55.19M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$90.35M 10-K · filed 2026-03-24 | |
| 2024-12-31 | -$75.14M 10-K · filed 2026-03-24 | |
| 2023-12-31 | -$36.32M 10-K · filed 2025-03-24 | |
| 2022-12-31 | -$55.19M 10-K · filed 2024-03-18 | -$57.58M 10-K · filed 2023-03-20 |
| 2021-12-31 | -$60.69M 10-K · filed 2023-03-20 | |
| 2020-12-31 | -$32.76M 10-K · filed 2022-03-01 | |
| 2019-12-31 | -$67.31M 10-K · filed 2021-03-25 | |
| 2018-12-31 | -$9.11M 10-K · filed 2020-03-12 | |
| 2017-12-31 | -$6.42M 10-K · filed 2020-03-12 | |
| 2016-12-31 | -$5.26M 10-K · filed 2019-03-07 | |
| 2015-12-31 | -$3.48M 10-K · filed 2018-03-12 | |
| 2014-12-31 | -$3.49M 10-K · filed 2017-03-09 | -$3.49M 10-K · filed 2015-03-16 |
| 2013-12-31 | $147.00K 10-K · filed 2016-03-14 | $147.28K 10-K · filed 2015-03-16 |
| 2012-12-31 | -$240.03K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |